首页> 外文期刊>Angiology: the Journal of Vascular Diseases >Cardiovascular risk assessment in diabetes mellitus: Comparison of the general framingham risk profile versus the World Health Organization/ International Society of Hypertension risk prediction charts in Arabs - Clinical implications
【24h】

Cardiovascular risk assessment in diabetes mellitus: Comparison of the general framingham risk profile versus the World Health Organization/ International Society of Hypertension risk prediction charts in Arabs - Clinical implications

机译:糖尿病患者的心血管风险评估:普通弗雷明汉风险概况与世界卫生组织/国际高血压协会阿拉伯人风险预测图表的比较-临床意义

获取原文
获取原文并翻译 | 示例
           

摘要

We estimated the prevalence of cardiovascular disease (CVD) risk and its clinical implications among 1 110 Omani patients with type 2 diabetes mellitus (DM) using 2 different CVD risk tools: the general Framingham risk profile (GFRP) and the joint World Health Organization/International Society of Hypertension (WHO/ISH) risk prediction charts. The GFRP tool identified higher proportion of patients compared with joint WHO/ISH tool at 10-year CVD risk 10% to <20% and at 20% to <30%. At CVD risk ≥30%, both assessment tools identified similar proportions of patients (22% vs 24%; P=.120). Compared with WHO/ISH charts, the GFRP identified almost double the number of men eligible for aspirin treatment at CVD risk thresholds of ≥10% (86% vs 43%). In women, the proportions were, 66% and 45%, respectively. For statins, the figures were, 60% and 37%, for men and 28% and 36%, for women. In conclusion, the GFRP overestimates the number of patients eligible for primary prevention of CVD compared with the joint WHO/ISH method.
机译:我们使用2种不同的CVD风险工具:一般的弗雷明汉风险简介(GFRP)和联合的世界卫生组织(World Health Organization /),估算了1 110名阿曼2型糖尿病(DM)患者中心血管疾病(CVD)的患病率及其临床意义。国际高血压学会(WHO / ISH)风险预测图。与10年CVD风险10%至<20%和20%至<30%的WHO / ISH联合工具相比,GFRP工具确定的患者比例更高。在CVD风险≥30%时,两种评估工具均可确定相似比例的患者(22%vs 24%; P = .120)。与WHO / ISH图表相比,GFRP在CVD风险阈值≥10%时,有资格接受阿司匹林治疗的男性人数几乎翻了一番(86%比43%)。在女性中,这一比例分别为66%和45%。对于他汀类药物,男性分别为60%和37%,女性为28%和36%。总之,与WHO / ISH联合方法相比,GFRP高估了可以进行CVD一级预防的患者人数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号